Frost Radar：人工智慧驅動的臨床試驗，2026 年

Frost Radar: Artificial Intelligence-Enabled Clinical Trials, 2026

出版日期: 2026年01月12日 | 出版商:

Frost & Sullivan | 英文 59 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

標竿管理體系旨在鼓勵企業行為創新，從而促進新業務的創建和成長。

人工智慧 (AI) 正在革新以技術驅動的藥物發現和開發領域。在臨床研究中，AI 的應用日益廣泛，涵蓋研究中心選擇、研究設計和通訊協定最佳化，以及病患招募和管理。由於數據是藥物發現和開發的核心，電子健康記錄和真實世界數據也有助於支持研究結果並提高藥物療效。 AI 可以從各種非結構化資料中建立結構化資料庫，從而簡化資料評估並提高試驗的安全性和效率。先進的生成式和基於代理的 AI 技術、真實世界數據以及協同駕駛的大規模語言模型，使得即時存取資料庫成為可能，從而將合適的患者配對到合適的臨床試驗中。

利用人工智慧驅動的解決方案進行臨床試驗設計、中心選擇、患者識別和保留，可以降低成本、提高效率，並透過遠端患者招募、管理和互動，促進向分散式試驗的過渡。互動式平台能夠提高患者依從性並增強保留率。在本次Frost Radar分析中， Frost & Sullivan甄選出專注於創新人工智慧技術以支持臨床試驗以及產生和獲取真實世界證據的公司，這些公司致力於解決高度成熟的臨床試驗行業面臨的關鍵挑戰。

Frost & Sullivan公司對產業內的眾多公司進行分析。根據領導力及其他特徵篩選出的公司將接受詳細分析，並根據10項成長和創新標準進行基準測試，以確定其在Frost Radar上的位置。本刊物呈現了每家公司在Frost Radar上的競爭概況，並考慮了它們的優勢以及最能發揮這些優勢的機會。

Artificial intelligence (AI) has been revolutionizing the technology-enabled drug discovery and development landscape. In clinical research, AI has been gaining traction across site selection, trial design and protocol optimization, and patient recruitment and management. Because data is the core discipline of drug development, electronic medical records and real-world evidence also support trial outcomes and improve drug efficiency. AI can create structured databases from disparate and unstructured sources, simplifying data assessment and enhancing trial safety and efficiency. Sophisticated generative and agentic AI-based technologies and real-world data and copilot-based large language models provide real-time database access to target the right patient to the right clinical trial.

AI-driven solutions used in clinical trial design, site selection, and patient identification and retention can reduce costs, increase efficiency, and support the transition to decentralized trials by means of remote patient recruitment, management, and engagement. Interactive platforms ensure better patient adherence and greater retention. For this Frost Radar analysis, Frost & Sullivan selected companies that reflect a sharp focus on innovative AI technologies for clinical trial support and real-world evidence generation and access and a goal to overcome the key challenges across the highly mature clinical trials industry.

Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar. The publication presents competitive profiles of each company on the Frost Radar considering their strengths and the opportunities that best fit those strengths.